Wedbush Reiterates Outperform and PT of $13 on Anacor Pharmaceuticals

by Emily Austin, Benzinga Staff Writer

June 29, 2011 9:48 AM | 13 seconds read | Make a Comment

Wedbush reiterated its Outperform rating on Anacor Pharmaceuticals

ANAC

. At the same time, Wedbush left its price target on the company's stock unchanged at $13. In today's trading, Anacor lost 3.04% of its values to trade around $6.37.

Market News and Data brought to you by Benzinga APIs

Posted In: Reiteration Analyst Ratings Anacor Wedbush

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Wedbush Reiterates Outperform and PT of $13 on Anacor Pharmaceuticals